Jump to content

Page values for "Gabapentin"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringGabapentin
brandStringNeurontin (IR), Gralise (ER), Horizant (gabapentin enacarbil ER)
structureFile
classesList of String, delimiter: ,[[:Category:Gabapentinoids|Gabapentinoid]] [[:Category:Anticonvulsants|Anticonvulsant]] [[:Category:Neuropathic pain medicines|Neuropathic pain medicine]]
mechanismString
usesString'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"'
starting_doseString300 mg PO at bedtime night 1, 300 mg BID day 2, 300 mg TID day 3; titrate to clinical effect, commonly 1800-3600 mg/day divided TID
preparationsStringCapsules 100, 300, 400 mg; tablets 600, 800 mg; oral solution 250 mg/5 mL; Gralise ER tablets 300, 600 mg (once-daily); Horizant ER tablets 300, 600 mg (gabapentin enacarbil, an inactive parent compound metabolized to gabapentin in vivo)
fda_maxString3600 mg/day; off-label doses higher are common but bioavailability saturates well below this
pill_idText
routesList of String, delimiter: ,Oral
onsetString1-2 weeks for neuropathic pain and anxiolytic effect; anticonvulsant effect at therapeutic plasma level
durationStringTID dosing for IR; once-daily for ER formulations
halflifeString5-7 hours'"`UNIQ--ref-00000029-QINU`"'
bioavailabilityString'''Saturable''' via the LAT-1 amino-acid transporter, producing nonlinear pharmacokinetics: ~60% at 300 mg single dose, falling to ~35% at 1200 mg single dose'"`UNIQ--ref-0000002A-QINU`"'
pregnancyStringLimited human data; some signal for cardiac malformations and developmental delay but confounded by maternal disease and polytherapy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString